Cellulitis - Pipeline Review, H1 2012

Global Markets Direct, June 2012, Pages: 31

Cellulitis – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Cellulitis - Pipeline Review, H1 2012', provides an overview of the Cellulitis therapeutic pipeline. This report provides information on the therapeutic development for Cellulitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cellulitis. 'Cellulitis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cellulitis.
- A review of the Cellulitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cellulitis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cellulitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cellulitis pipeline depth and focus of Cellulitis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Cellulitis Therapeutic Products under Development, Key Players in Cellulitis Therapeutics, Cellulitis Pipeline Overview, Cellulitis Pipeline, Cellulitis Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cellulitis Overview
Therapeutics Development
An Overview of Pipeline Products for Cellulitis
Cellulitis Therapeutics under Development by Companies
Cellulitis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Cellulitis Therapeutics – Products under Development by Companies
Cellulitis Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Cellulitis Therapeutics Development
Durata Therapeutics Inc.
Cellulitis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Dalbavancin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Moxifloxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cefazolin + Probenecid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Trimethoprim + Sulfamethoxazole + Clindamycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cellulitis Therapeutics – Drug Profile Updates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Cellulitis, H1 2012
Products under Development for Cellulitis – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Durata Therapeutics Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Cellulitis Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Cellulitis, H1 2012
Products under Development for Cellulitis – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Rhinitis - Pipeline Review, H1 2013
• Alzheimer's Disease – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Rotavirus Infections – Pipeline Review, H1 2013
• Febrile Neutropenia - Pipeline Review, H1 2013
• Bronchopulmonary Dysplasia - Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Burns - Pipeline Review, H1 2013
• Scar - Pipeline Review, H1 2013
• Constipation - Pipeline Review, H1 2013